GORMAN KEVIN CHARLES sold NBIX

January 27, 2025 · Form 4 insider transaction

GORMAN KEVIN CHARLES sold 146,105 shares of Neurocrine Biosciences, Inc. at $149.46 per share, a transaction worth $21.84M. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
146,105
Price
$149.46
Total value
$21.84M
Role
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJanuary 27, 2025
Filing dateJanuary 29, 2025
Shares owned after514,596
OwnershipDirect
10b5-1 planYes
AmendedNo

Footnotes

The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.; Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $147.20 to $151.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.; 514,596 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power.

View the original Form 4 on SEC EDGAR